A study to find out the safety, tolerability and interaction of RO7268489 with body (including the effect of itraconazole on RO7268489) and also what the body does to RO7268489 after oral intake by healthy participants

Phase 1

• Conditions: Healthy volunteers; Not Applicable

• Registration Number: ISRCTN14119236
• Lead Sponsor: F. Hoffmann-La Roche Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-05-10
• Last Update Posted: 18 June 2024
• Study Completion: 2025-03-19

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

1.Male or female participants aged 18 - 64 years, who are overtly healthy (defined by absence of evidence of any active or chronic disease)
2.BMI within the range of 18.5 to 30 kg/m² (inclusive)

Exclusion Criteria

1.History of malignancy in the past 5 years.
2.History of any clinically significant psychiatric disorder.
3.History of severe unpleasant experience following the use of cannabis-containing products
4.History or evidence of any medical condition potentially altering the absorption, metabolism, or elimination of drugs.
5.Any contraindications for magnetic resonance imaging (MRI) scans or any brain/head abnormalities restricting MRI eligibility (Part 1 only).
6.Vaccination within 2 weeks prior to Day 1 including influenza and/or SARS-CoV-2/ COVID-19 vaccination

Study & Design

• Study Type: Interventional
• Study Design: Not specified